Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials
Background: The infusional LV5FU2 and Arbeitsgemeinschaft Internische Onkologie (AIO) regimens are used widely in the treatment of advanced colorectal cancer. Irinotecan combined with these regimens increases survival in front-line treatment. Irinotecan also improves survival in second-line treatmen...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2004-07, Vol.15 (7), p.1013-1017 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1017 |
|---|---|
| container_issue | 7 |
| container_start_page | 1013 |
| container_title | Annals of oncology |
| container_volume | 15 |
| creator | Mitry, E. Douillard, J.-Y. Van Cutsem, E. Cunningham, D. Magherini, E. Mery-Mignard, D. Awad, L. Rougier, P. |
| description | Background: The infusional LV5FU2 and Arbeitsgemeinschaft Internische Onkologie (AIO) regimens are used widely in the treatment of advanced colorectal cancer. Irinotecan combined with these regimens increases survival in front-line treatment. Irinotecan also improves survival in second-line treatment. Patients and methods: Univariate and multivariate analyses based on the individual data of 602 patients included in two phase III trials were performed to determine predictive factors of survival in advanced colorectal cancer. Results: Three factors were independently associated with a better progression-free survival: weight loss |
| doi_str_mv | 10.1093/annonc/mdh267 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66642759</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66642759</sourcerecordid><originalsourceid>FETCH-LOGICAL-c328t-75e5a7a25965b39aa1d7e11d5738f523a2ab86b7735aae9e2723bc5977c15dc13</originalsourceid><addsrcrecordid>eNpNkc1uEzEURi0EoqGwZIu8gd1Q_8R2zA5VtI0UCRaAKjbWHdujGCZ2sD0DfZq-Ki6JCKsrfT46V74fQi8peUuJ5hcQY4r2Yue2TKpHaEGF1N2KLOljtCCa8U4JvjxDz0r5TgiRmumn6IwKRgTVfIHuP2Xvgq1h9ngAW1MuOA24THkOM4w4RLyHGnysBf8KdYvBzRCtd9imMWVva4PsQ5LfYYiNd2EObmqpgwotgvGuhL9SSdhJFqIdJ9c8bUPIIabqmwbvt1A8Xq_XuOYAY3mOngxt-BfHeY6-XH34fHnTbT5ery_fbzrL2aq2T3oBCpjQUvRcA1CnPKVOKL4aBOPAoF_JXikuALz2TDHeW6GVslQ4S_k5enPw7nP6OflSzS4U68cRok9TMVLKJVNCN7A7gDanUrIfzD6HHeQ7Q4l5aMQcGjGHRhr_6iie-p13J_pYQQNeHwEoFsYht2OG8h-neaPUaXEo1f_-9w75h2lrlDA3t9_MUt9-3dAragT_A0gSp8U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66642759</pqid></control><display><type>article</type><title>Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Mitry, E. ; Douillard, J.-Y. ; Van Cutsem, E. ; Cunningham, D. ; Magherini, E. ; Mery-Mignard, D. ; Awad, L. ; Rougier, P.</creator><creatorcontrib>Mitry, E. ; Douillard, J.-Y. ; Van Cutsem, E. ; Cunningham, D. ; Magherini, E. ; Mery-Mignard, D. ; Awad, L. ; Rougier, P.</creatorcontrib><description>Background: The infusional LV5FU2 and Arbeitsgemeinschaft Internische Onkologie (AIO) regimens are used widely in the treatment of advanced colorectal cancer. Irinotecan combined with these regimens increases survival in front-line treatment. Irinotecan also improves survival in second-line treatment. Patients and methods: Univariate and multivariate analyses based on the individual data of 602 patients included in two phase III trials were performed to determine predictive factors of survival in advanced colorectal cancer. Results: Three factors were independently associated with a better progression-free survival: weight loss <5% [hazard ratio (HR) 1.25; 95% confidence interval (CI) 1.00–1.58], World Health Organization performance status (WHO PS) 0–1 (HR 1.29; 95% CI 1.08–1.54) and irinotecan (CPT-11)-containing regimens (HR 1.48; 95% CI 1.03–2.13). Five factors were independently associated with a better overall survival: weight loss <5% (HR 1.67; 95% CI 1.29–2.14), WHO PS 0–1 (HR 1.88; 95% CI 1.27–2.75), one or two metastatic sites (HR 1.24; 95% CI 1.01–1.53), alkaline phosphatase values not over twice the normal range (HR 1.71; 95% CI 1.30–2.24) and CPT-11-containing regimens (HR 1.31; 95% CI 1.07–1.61). Conclusions: The present analysis confirms that CPT-11-based chemotherapy regimens are independently associated with a better survival in patients with advanced colorectal cancer. Age was not identified as a prognostic factor in this analysis.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdh267</identifier><identifier>PMID: 15205193</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Antineoplastic Agents, Phytogenic - therapeutic use ; Biological and medical sciences ; Camptothecin - analogs & derivatives ; Camptothecin - therapeutic use ; chemotherapy ; colorectal neoplasms ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - mortality ; Drug Therapy, Combination ; Female ; Fluorouracil - therapeutic use ; Humans ; Irinotecan ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Pharmacology. Drug treatments ; Prognosis ; prognostic factors ; Randomized Controlled Trials as Topic ; Survival Analysis ; Survival Rate ; Treatment Outcome ; Tumors</subject><ispartof>Annals of oncology, 2004-07, Vol.15 (7), p.1013-1017</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c328t-75e5a7a25965b39aa1d7e11d5738f523a2ab86b7735aae9e2723bc5977c15dc13</citedby><cites>FETCH-LOGICAL-c328t-75e5a7a25965b39aa1d7e11d5738f523a2ab86b7735aae9e2723bc5977c15dc13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15939337$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15205193$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mitry, E.</creatorcontrib><creatorcontrib>Douillard, J.-Y.</creatorcontrib><creatorcontrib>Van Cutsem, E.</creatorcontrib><creatorcontrib>Cunningham, D.</creatorcontrib><creatorcontrib>Magherini, E.</creatorcontrib><creatorcontrib>Mery-Mignard, D.</creatorcontrib><creatorcontrib>Awad, L.</creatorcontrib><creatorcontrib>Rougier, P.</creatorcontrib><title>Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Background: The infusional LV5FU2 and Arbeitsgemeinschaft Internische Onkologie (AIO) regimens are used widely in the treatment of advanced colorectal cancer. Irinotecan combined with these regimens increases survival in front-line treatment. Irinotecan also improves survival in second-line treatment. Patients and methods: Univariate and multivariate analyses based on the individual data of 602 patients included in two phase III trials were performed to determine predictive factors of survival in advanced colorectal cancer. Results: Three factors were independently associated with a better progression-free survival: weight loss <5% [hazard ratio (HR) 1.25; 95% confidence interval (CI) 1.00–1.58], World Health Organization performance status (WHO PS) 0–1 (HR 1.29; 95% CI 1.08–1.54) and irinotecan (CPT-11)-containing regimens (HR 1.48; 95% CI 1.03–2.13). Five factors were independently associated with a better overall survival: weight loss <5% (HR 1.67; 95% CI 1.29–2.14), WHO PS 0–1 (HR 1.88; 95% CI 1.27–2.75), one or two metastatic sites (HR 1.24; 95% CI 1.01–1.53), alkaline phosphatase values not over twice the normal range (HR 1.71; 95% CI 1.30–2.24) and CPT-11-containing regimens (HR 1.31; 95% CI 1.07–1.61). Conclusions: The present analysis confirms that CPT-11-based chemotherapy regimens are independently associated with a better survival in patients with advanced colorectal cancer. Age was not identified as a prognostic factor in this analysis.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Phytogenic - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Camptothecin - analogs & derivatives</subject><subject>Camptothecin - therapeutic use</subject><subject>chemotherapy</subject><subject>colorectal neoplasms</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - mortality</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Fluorouracil - therapeutic use</subject><subject>Humans</subject><subject>Irinotecan</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>prognostic factors</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Survival Analysis</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkc1uEzEURi0EoqGwZIu8gd1Q_8R2zA5VtI0UCRaAKjbWHdujGCZ2sD0DfZq-Ki6JCKsrfT46V74fQi8peUuJ5hcQY4r2Yue2TKpHaEGF1N2KLOljtCCa8U4JvjxDz0r5TgiRmumn6IwKRgTVfIHuP2Xvgq1h9ngAW1MuOA24THkOM4w4RLyHGnysBf8KdYvBzRCtd9imMWVva4PsQ5LfYYiNd2EObmqpgwotgvGuhL9SSdhJFqIdJ9c8bUPIIabqmwbvt1A8Xq_XuOYAY3mOngxt-BfHeY6-XH34fHnTbT5ery_fbzrL2aq2T3oBCpjQUvRcA1CnPKVOKL4aBOPAoF_JXikuALz2TDHeW6GVslQ4S_k5enPw7nP6OflSzS4U68cRok9TMVLKJVNCN7A7gDanUrIfzD6HHeQ7Q4l5aMQcGjGHRhr_6iie-p13J_pYQQNeHwEoFsYht2OG8h-neaPUaXEo1f_-9w75h2lrlDA3t9_MUt9-3dAragT_A0gSp8U</recordid><startdate>20040701</startdate><enddate>20040701</enddate><creator>Mitry, E.</creator><creator>Douillard, J.-Y.</creator><creator>Van Cutsem, E.</creator><creator>Cunningham, D.</creator><creator>Magherini, E.</creator><creator>Mery-Mignard, D.</creator><creator>Awad, L.</creator><creator>Rougier, P.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040701</creationdate><title>Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials</title><author>Mitry, E. ; Douillard, J.-Y. ; Van Cutsem, E. ; Cunningham, D. ; Magherini, E. ; Mery-Mignard, D. ; Awad, L. ; Rougier, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c328t-75e5a7a25965b39aa1d7e11d5738f523a2ab86b7735aae9e2723bc5977c15dc13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Phytogenic - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Camptothecin - analogs & derivatives</topic><topic>Camptothecin - therapeutic use</topic><topic>chemotherapy</topic><topic>colorectal neoplasms</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - mortality</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Fluorouracil - therapeutic use</topic><topic>Humans</topic><topic>Irinotecan</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>prognostic factors</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Survival Analysis</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mitry, E.</creatorcontrib><creatorcontrib>Douillard, J.-Y.</creatorcontrib><creatorcontrib>Van Cutsem, E.</creatorcontrib><creatorcontrib>Cunningham, D.</creatorcontrib><creatorcontrib>Magherini, E.</creatorcontrib><creatorcontrib>Mery-Mignard, D.</creatorcontrib><creatorcontrib>Awad, L.</creatorcontrib><creatorcontrib>Rougier, P.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mitry, E.</au><au>Douillard, J.-Y.</au><au>Van Cutsem, E.</au><au>Cunningham, D.</au><au>Magherini, E.</au><au>Mery-Mignard, D.</au><au>Awad, L.</au><au>Rougier, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2004-07-01</date><risdate>2004</risdate><volume>15</volume><issue>7</issue><spage>1013</spage><epage>1017</epage><pages>1013-1017</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Background: The infusional LV5FU2 and Arbeitsgemeinschaft Internische Onkologie (AIO) regimens are used widely in the treatment of advanced colorectal cancer. Irinotecan combined with these regimens increases survival in front-line treatment. Irinotecan also improves survival in second-line treatment. Patients and methods: Univariate and multivariate analyses based on the individual data of 602 patients included in two phase III trials were performed to determine predictive factors of survival in advanced colorectal cancer. Results: Three factors were independently associated with a better progression-free survival: weight loss <5% [hazard ratio (HR) 1.25; 95% confidence interval (CI) 1.00–1.58], World Health Organization performance status (WHO PS) 0–1 (HR 1.29; 95% CI 1.08–1.54) and irinotecan (CPT-11)-containing regimens (HR 1.48; 95% CI 1.03–2.13). Five factors were independently associated with a better overall survival: weight loss <5% (HR 1.67; 95% CI 1.29–2.14), WHO PS 0–1 (HR 1.88; 95% CI 1.27–2.75), one or two metastatic sites (HR 1.24; 95% CI 1.01–1.53), alkaline phosphatase values not over twice the normal range (HR 1.71; 95% CI 1.30–2.24) and CPT-11-containing regimens (HR 1.31; 95% CI 1.07–1.61). Conclusions: The present analysis confirms that CPT-11-based chemotherapy regimens are independently associated with a better survival in patients with advanced colorectal cancer. Age was not identified as a prognostic factor in this analysis.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>15205193</pmid><doi>10.1093/annonc/mdh267</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2004-07, Vol.15 (7), p.1013-1017 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66642759 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Antineoplastic agents Antineoplastic Agents, Phytogenic - therapeutic use Biological and medical sciences Camptothecin - analogs & derivatives Camptothecin - therapeutic use chemotherapy colorectal neoplasms Colorectal Neoplasms - drug therapy Colorectal Neoplasms - mortality Drug Therapy, Combination Female Fluorouracil - therapeutic use Humans Irinotecan Male Medical sciences Middle Aged Multivariate Analysis Pharmacology. Drug treatments Prognosis prognostic factors Randomized Controlled Trials as Topic Survival Analysis Survival Rate Treatment Outcome Tumors |
| title | Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T06%3A00%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictive%20factors%20of%20survival%20in%20patients%20with%20advanced%20colorectal%20cancer:%20an%20individual%20data%20analysis%20of%20602%20patients%20included%20in%20irinotecan%20phase%20III%20trials&rft.jtitle=Annals%20of%20oncology&rft.au=Mitry,%20E.&rft.date=2004-07-01&rft.volume=15&rft.issue=7&rft.spage=1013&rft.epage=1017&rft.pages=1013-1017&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdh267&rft_dat=%3Cproquest_cross%3E66642759%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66642759&rft_id=info:pmid/15205193&rfr_iscdi=true |